| Title |
Obinutuzumab Plus Chemotherapy Compared with Rituximab Plus Chemotherapy in Previously Untreated Italian Patients with Advanced Follicular Lymphoma at Intermediate–High Risk: A Cost-Effectiveness Analysis
|
|---|---|
| Published in |
ClinicoEconomics and Outcomes Research: CEOR, July 2021
|
| DOI | 10.2147/ceor.s317885 |
| Pubmed ID | |
| Authors |
Marco Bellone, Lorenzo Pradelli, Stefano Molica, Adele Emanuela De Francesco, Daniela Ghislieri, Emanuele Guardalben, Antonietta Caputo |
X Demographics
The data shown below were collected from the profiles of 2 X users who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Unknown | 2 | 100% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Members of the public | 2 | 100% |
Mendeley readers
The data shown below were compiled from readership statistics for 11 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Unknown | 11 | 100% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Student > Bachelor | 3 | 27% |
| Unspecified | 1 | 9% |
| Researcher | 1 | 9% |
| Student > Master | 1 | 9% |
| Unknown | 5 | 45% |
| Readers by discipline | Count | As % |
|---|---|---|
| Nursing and Health Professions | 2 | 18% |
| Biochemistry, Genetics and Molecular Biology | 1 | 9% |
| Unspecified | 1 | 9% |
| Psychology | 1 | 9% |
| Neuroscience | 1 | 9% |
| Other | 0 | 0% |
| Unknown | 5 | 45% |
Attention Score in Context
This research output has an Altmetric Attention Score of 2. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 30 July 2021.
All research outputs
#16,785,164
of 25,462,162 outputs
Outputs from ClinicoEconomics and Outcomes Research: CEOR
#313
of 525 outputs
Outputs of similar age
#260,174
of 453,972 outputs
Outputs of similar age from ClinicoEconomics and Outcomes Research: CEOR
#9
of 16 outputs
Altmetric has tracked 25,462,162 research outputs across all sources so far. This one is in the 32nd percentile – i.e., 32% of other outputs scored the same or lower than it.
So far Altmetric has tracked 525 research outputs from this source. They typically receive a lot more attention than average, with a mean Attention Score of 12.0. This one is in the 37th percentile – i.e., 37% of its peers scored the same or lower than it.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 453,972 tracked outputs that were published within six weeks on either side of this one in any source. This one is in the 39th percentile – i.e., 39% of its contemporaries scored the same or lower than it.
We're also able to compare this research output to 16 others from the same source and published within six weeks on either side of this one. This one is in the 43rd percentile – i.e., 43% of its contemporaries scored the same or lower than it.